About Us
Rohto Advanced Research Hong Kong Limited (ARHK) was established in January 2019 by a Japanese company called ROHTO Pharmaceutical Co., Ltd (ROHTO). ROHTO’s core areas of business are OTC drugs (over-the-counter drugs), skincare and functional foods.
In addition to research and development in the fields of eye care, skin care, internal medicine, and food in the existing Health & Beauty business, ROHTO is taking on the challenge of a wide range of fields to generate innovation in our various businesses.
One of the ROHTO's primary research focuses is regenerative medicine. In 2017, ROHTO started its first clinical trial using allogenic adipose-derived mesenchymal stromal cells against liver cirrhosis. In 2020, ROHTO also began a clinical trial targeting severe COVID-19 pneumonia, which entered Phase II trials in 2021. Multiple ongoing clinical trials against various indications are currently taking place in Japan.
ARHK, in line with the strategic planning and development of regenerative medicine and related businesses, leverages ROHTO's expertise and cutting-edge technologies to contribute to scientific research and promote people's well-being. Currently, ARHK is engaged in collaborative scientific research on mesenchymal stromal cells with multiple parties in Hong Kong and globally.
We aim to expand our R&D activities worldwide and eagerly looks forward to discovering and encountering novel technologies.